BREO ELLIPTA FLUTICASONE-VILANTEROL

$106.22

Description

Asthma: RELVARE is indicated for the maintenance treatment of asthma.

COPD: RELVARE is indicated for the maintenance treatment of airway obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and / or emphysema, and to reduce COPD exacerbations in patients with a history of exacerbations.

BREO ELLIPTA FLUTICASONE-VILANTEROL

Reviews

There are no reviews yet.

Be the first to review “BREO ELLIPTA FLUTICASONE-VILANTEROL”

Your email address will not be published. Required fields are marked *

Scroll to top